

THE FUTURE OF SCIENTIFIC DISSEMINATION

Herbert Y. Kressel, MD

Harvard Medical School

Maximillian F. Reiser, MD


Ludwig Maximilians University Munich

The Future of Scientific Dissemination

- ▣ Reporting Guidelines - HYK
- ▣ New ways of presenting information - HYK
- ▣ Open Access - MFR
- ▣ Alternative peer review - MFR
- ▣ Measuring impact - MFR
- ▣ Preprint Servers - HYK
- ▣ Collaboration Sites - HYK
- ▣ Data Sharing repositories - HYK


Special Thanks To

- ▣ Emma Brink, John Wiley & Sons
- ▣ Paula Del Campo, Digital Science Technologies
- ▣ Jeremy Nielsen, RSNA



Reporting Standards are Desirable

- “Standards governing the content and format of statistical aspects should be developed to guide authors in the preparation of manuscripts.”
-O’Fallon et al 1978, Biometrics 34:687-95
- “... editors could greatly improve the reporting of clinical trials by providing authors with a list of items that they expected to be strictly reported.”
-DerSimonian et al 1982, NEJM 306:1332-7
- “An obvious proposal is to suggest that editors ...make up a check-list for authors....”
-Zelen 1989, J Clin Oncol 7:827-8



Reporting Guidelines

STARD 2015: An Updated List
of Essential Items for Reporting
Diagnostic Accuracy Studies¹

Radiology



STROBE Statement

Strengthening the reporting of observational studies in epidemiology



CONSORT TRANSPARENT REPORTING of TRIALS



PRISMA

TRANSPARENT REPORTING OF SYSTEMATIC REVIEWS AND META-ANALYSES

Search for reporting guidelines

Use your browser's Back button to return to your search results



CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials

Reporting guideline
provided for?
(i.e. exactly what the
authors state in the
paper)

Parallel group randomised trials

[CONSORT checklist \(Word\)](#)

[CONSORT flow diagram \(Word\)](#)

Full bibliographic
reference


Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.

Ann Int Med. 2010;152(11):726-32. PMID: [20335313](#)




Reporting guidelines for main study types

Randomised trials	CONSORT	Extensions
Observational studies	STROBE	Extensions
Systematic reviews	PRISMA	Extensions
Case reports	CARE	
Qualitative research	SRQR	COREQ
Diagnostic / prognostic studies	STARD	TRIPOD
Quality improvement studies	SQUIRE	
Economic evaluations	CHEERS	
Animal pre-clinical studies	ARRIVE	
Study protocols	SPIRIT	PRISMA-P



Guidelines Improve Reporting


- Help identify the presence and nature of bias
- Help identify methodological problems (sample size, inappropriate analysis)
- Help ensure that the descriptions of methods are adequate for other to reproduce
- They do **NOT** ensure that a study is novel or important or interesting



Questions


- ▣ Have you used Reporting Guideline?
- ▣ When? When designing, writing, or submitting the study
- ▣ Were they helpful? Which ones?
- ▣ Any formal training in using these?

New ways of presenting information



- ▣ Visual Abstracts
- ▣ Podcasts
- ▣ Video podcasts
- ▣ Enhanced pdf's
- ▣ Semantic Enrichment

Visual Abstracts



thebmj Visual Abstract



Randomised controlled trial



Primary outcome

Weight change from baseline to 12 months

Clinical significance

Defined as a 4 kg difference between groups

DROPLET trial

Doctor Referral of Overweight People to Low Energy total diet replacement Treatment

278

Patients with BMI >30

Sourced from 10 GP practices

Aged >18 years



Randomisation

138

Total Diet Replacement

12 week programme.
8 weeks TDR (810 kcal/day).
4 weeks food re-introduction.
Regular behavioural support.

140

Usual Care

Series of appointments
with a practice nurse
for behavioural weight
management advice.

Difference between arms

Weight change (mean)

-10.7 kg

-7.2 kg

P<0.001

-3.1 kg

Proportion reporting adverse events

51.5%

21.8% less

P<0.001

29.7%

Adverse events (moderate or worse)

11.2%

1.1% less

P=0.85

12.3%

Referral to a total diet replacement programme with support provided by a commercial provider is an effective intervention for the routine treatment of obesity.

thebmj

Read the full article online

<http://bit.ly/BMJdrop>

© 2018 BMJ Publishing group Ltd.

Visual Abstracts



What is the effect of an algorithm used to define antibiotic choice and duration on clinical success and serious adverse events in patients with staphylococcal bacteremia?

CONCLUSION The use of an algorithm to guide testing and treatment compared with usual care resulted in a noninferior rate of clinical success; there was not a significant difference in serious adverse events.

POPULATION

283 Men
226 Women



Adults aged 18 years and older and had 1 or more blood culture positive for either *S aureus* or coagulase-negative staphylococci
Mean age: 56.6 years

LOCATIONS

16

Academic medical centers in Spain and the United States



INTERVENTION

509 Patients enrolled

255

Algorithm-based therapy
Predefined diagnostic evaluation, antibiotic selection, and duration of therapy

254

Usual practice
Unrestrained choice of antibiotics and duration of therapy

COPRIMARY OUTCOMES

Clinical success (blinded adjudication committee and tested for noninferiority with a 1.5% margin)

FINDINGS

Clinical success

Algorithm-based therapy

82.0%

Usual practice

81.5%

Difference: 0.5%

(1-sided 97.5% CI: -4.2% to ∞)

Serious adverse events

Algorithm-based therapy

32.5%

Usual practice

28.3%

Difference: 4.2%

(95% CI: -3.8% to 12.2%)

JAMA • @JAMA • current • Sep 28 • Rates in intention-to-treat population (tested for noninferiority)

This noninferiority trial compares the effects on clinical success and adverse events of an algorithm that defines diagnostic evaluation, antibiotic selection, and duration of therapy for staphylococcal bacteremia vs standard clinical care. [jama/2020.11111](https://doi.org/10.1001/jama.2020.11111) #VisualAbstract



18



36



Radiology

Radiology is a monthly journal devoted to clinical radiology and allied sciences, owned and published by the Radiological Society of North America, Inc.

[HOME](#) | [CURRENT](#) | [ARCHIVE](#) | [COLLECTIONS](#) | [COVER GALLERY](#) | [中国 \(ABSTRACTS\)](#) | [RADIOGRAPHICS](#)

Institution: rsna2

User Name

Password

[LOG-IN](#)

[Go](#)

[Advanced Search](#)



Hear What We Think

Listen to the editor, deputy editors, and authors discuss the importance and context of selected articles from current and recent issues of *Radiology*

Current Issue

January 2011, 258 (1)

[Alert me to new issues of Radiology](#)

Subscribe to the [RSS feed](#) or via the [iTunes store](#) if you have the iTunes media player ([a free download](#)).

JANUARY 2011

Part 1 of 2

Moderator: Herbert Y. Kressel, MD; Editor of *Radiology*

Participant: David B. Larson, MD, MBA, *Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio*

Article Discussed: National trends in CT use in the emergency department: 1995-2007. *Larson DB, Johnson LW, Schnell BM, Salisbury SR, Forman HP.* *Radiology* 2011;258(1): 164-173. [[Full Text](#)] | [[Abstract](#)]

[Video Version](#) | Opens in a new window

[[Watch Part 1](#)] | Duration: 11:14

Audio-only Version



[[Download the audio mp3](#)] | Duration: 11:14

+ [About Radiology](#)

+ [Access](#)

- [Resources for Readers](#)

[Future TOC](#)

[E-mail Alerts](#)

[Read E-letters](#)

[Feedback](#)

Part 2 of 2


Moderator: David E. Kellman, MD, Deputy Editor of *Radiology* [[Watch Part 2](#)] | Duration: 6:00



readcube

What is ReadCube Papers?

- Tools for Researchers by Researchers
- Reference Management tools - organize, discover, read and access PDFs
- Cite while you write functionality



Content Delivery: Enhanced PDF technology

Save articles to your free ReadCube library

Supplementary information and other valuable supporting article data, just a click away.

Download full PDF to save it on your desktop

References made clickable in line with full list available in expandable menu

Full citation history

Access saved articles directly in left panel or via ReadCube's free web, mobile or desktop apps.

The screenshot displays the ReadCube interface for an article titled "Battery by a Nanogenerator with 20 V Output" from the journal Advanced Materials. The interface is divided into several sections: a top navigation bar with options like "My Library", "Download PDF", "Add To Library", "Supplements", "References", and "Cited By"; a left sidebar with "readcube" logo and "Now Reading" status; a main article area showing the title, authors (Youfan Hu, Long Lin, Yan Zhang, and Zhong Lin Wang), and the abstract; and a right sidebar with "Notes", "Figures (4)", "Go to article page", "Altmetric (14)", "Export Citation", and "Related Articles". The article text discusses self-powered nanotechnology and nanogenerators. A bottom panel shows a "PDF viewing menu" with options for zoom, page rotation, full screen, and printing. A "Clickable inline figures" section shows a figure that can be expanded to a full screen viewer.

Summary of notes and highlights.

Full screen figure browser.

Return to abstract page.

Integrated social sharing metrics from Altmetric.

Export citation in RIS, BibTeX, EndNote, Papers and Mendeley formats.

Related articles links to other articles that may be of interest.

Highlighting and annotation tools enable interactive reading experience.

PDF viewing menu including zoom, page rotation, full screen and printing options.

Clickable inline figures which expands to full screen viewer.

References made clickable in line with full list available in expandable menu.

Clickable author details enabling quick look up and cross search of information.

Content Sharing: Rights-managed content delivery technology

- ▣ Launch partner: SpringerNature
- ▣ SharedIt:
 - Distribution of rights-managed links to content
 - View-only full text access to content
- ▣ 3 forms of sharing
 - Peer to Peer
 - Media Referrals
 - Author



Radlex: Related Content

Creating connections and relationships
between terms/concepts.

> contrast agent

▼ Imaging modality

4-D flow imaging

brachytherapy

chemical shift imaging

▼ cholangiopancreatography

CT cholangiopancreatography

MR cholangiopancreatography

collimator

computed tomography

contrast enhanced CT

▼ RELATIONSHIPS

BROADER CONCEPTS

Imaging modality

NARROWER CONCEPTS

CT cholangiopancreatography

MR cholangiopancreatography

RELATED CONCEPTS

pancreatic cancer

Radlex: Related Content

Seeing the terms and
concepts in context.

PREVIEW OF CHOLANGIOPANCREATOGRAPHY



1-46 / 46



Preoperative diagnosis with MR **cholangiopancreatography** or endoscopic retrograde **cholangiopancreatography** is critical to avoid bile duct injury. Gallbladder cancer is an uncommon malignancy that is usually diagnosed at an advanced stage.

If there is clinical suspicion for biliary obstruction on the basis of laboratory test results but no ductal dilatation is visible at US, magnetic resonance **cholangiopancreatography** (MRCPMR **cholangiopancreatography**) should be performed because it is a more sensitive and specific test.

The result is focal or diffuse bile duct wall thickening, mostly associated with stenosis and upstream dilatation, findings that are readily

Radlex: Related Content

Comparing articles in the test environment.

Intraductal Papillary Mucinous Neoplasms o...

Editor's Recognition Awards

Murphy's Law: What Can Go Wrong in the G...

Nonvascular Post-Liver Transplantation Co...

Radiology Editorial Board 2015

Combining in Vitro Diagnostics with in Vivo I...

Manuscript Reviewers & Notes of Thanks

Diffusion-weighted MR Imaging of the Pan... 0.75

Incidental Pancreatic Cystic Lesions: Is The... 0.64

IgG4-related Disease from Head to Toe 0.63

Combining in Vitro Diagnostics with in Vivo... 0.6

Targeted Screening of Individuals at High ... 0.34


Nonvascular Post-Liver Transplantation C... 0.32

Curtis Elmore's Journey to the Discovery of...

Radlex: Related Content

Comparing “fingerprints.”

Thesaurus_Concept			
MR cholangiopancreatography	1.607	MR cholangiopancreatography	1.448
main pancreatic duct	1.575	main pancreatic duct	1.412
fast spin-echo	1.494	fast spin-echo	1.458
contrast enhanced MR	1.478	contrast enhanced MR	1.373
pancreatic duct	1.429	pancreatic duct	1.26
magnetic resonance imaging	1.337	magnetic resonance imaging	1.321
pancreatitis	1.275	pancreatitis	1.232
diffusion-weighted imaging	1.244	diffusion-weighted imaging	1.274



41-year-old woman with **cirrhosis** and **pseudothrombosis** of **portal vein** and **superior mesenteric vein**. Arterial phase helical CT scan near **pancreas** shows apparent **superior mesenteric**.

Anatomic Location

Findings

- ⊕ Visual Features
- ⊕ Morphologic and Physiologic Processes

Diagnoses and Etiologies

- ⊕ Congenital and Developmental Diseases
- ⊕ Infectious and Inflammatory Diseases
- ⊕ Neoplastic Disease
- ⊕ **Chronic Infiltrative Lung Disease**
 - ⊕ **interstitial pneumonias**
 - acute interstitial pneumonia
 - desquamative interstitial pneumonia
 - usual interstitial pneumonia
 - cryptogenic organizing pneumonia**
 - respiratory bronchiolitis-associated interstitial pneumonia
 - nonspecific interstitial pneumonia
 - lymphocytic interstitial pneumonia
- ⊕ pneumoconioses

Findings

Visual Features

Modality Related

- ⊕ Finding Related Features
- ⊕ Radioopacity
- ⊕ Attenuation
- ⊕ Density
- ⊕ Echogenicity
- ⊕ Signal Characteristics
- ⊕ Flow Characteristics
- ⊕ Enhancement
- ⊕ Pattern
- ⊕ Artifacts
- ⊕ Morphologic and Physiologic Processes
- ⊕ Diagnoses and Etiologies

Image Acquisition/Processing/Display

Examination Type


Technique

- Imaging equipment manufacturer
- Imaging equipment model
- Imaging parameters
- Radiation dose
- Date and time of image acquisition
- Contrast agents administered
- Medications
- Patient position

- ⊕ Image Processing
- ⊕ Observer Comments
- Location on the image

Axes of indexing


- *Anatomy*
- *Disease*
- *Image findings*
- *Modality*




Questions – New Ways of Presenting Information

- ▣ Have you personally used : visual abstracts, audio podcasts? video podcasts? Symantec enrichment? Enhanced Content delivery, e.g. ReadCube?
- ▣ Which have been most valuable to you?

Preprint Servers



Our tools offer support at every stage of the research cycle



Scholarly Collaboration Networks




Academia.edu
share research



MENDELEY

WILEY




Research Gate (RG)

- ▣ Social networking site for scientists and investigators 15 Million users
- ▣ Share papers, ask questions, find collaborators
- ▣ Member user profiles may include research outputs including, papers, proposals, software, and data
- ▣ Aggressive solicitation of user profiles, may make unsolicited profiles
- ▣ RG criticized for failing to provide safeguards against predatory publishing

SciHub




WILEY



Sci Hub


- ▣ Founded in 2011 by Kazakhstani graduate student in response to paywalls
- ▣ Pirate website – disregards Copyright
- ▣ In 2016, 200,000 requests per day
- ▣ 62 million papers in collection
- ▣ 69% of all published papers
- ▣ Under repeated litigation by publishers and professional societies. URL keeps changing




Preprint Servers, Collaboration Networks - Questions

- ▣ What has been your experience with scholarly collaboration networks such as Research Gate, Mendeley, Academia.edu?
- ▣ What about preprint such as servers ChemArxiv.org, arXiv.org, bioRxiv?
- ▣ Any problems with RG or SciHub?


Data Sharing






IOM Report: Journals Should

- ▣ Require authors of primary and secondary analyses of Clinical trial Data to:
 - Document that they have submitted a data sharing plan meeting WHO requirements
 - Commit to releasing analytic data within a specified time period
 - Manuscripts derived from existing data sets must cite appropriately



ICMJE Statement

- ▣ There is an ethical obligation to responsibly share data generated by **interventional clinical trials** because participants have put themselves at risk.
- ▣ Clinical trial defined as as any research project that prospectively assigns people or a group of people to an intervention, with or without concurrent comparison or control groups, to study the cause-and-effect relationship between a health-related intervention *and* a health outcome.



Data sharing statements must indicate:

- ▣ Whether individual de-identified participant data (including data dictionaries) will be shared
- ▣ What data in particular will be shared
- ▣ Whether additional, related documents will be available (e.g., study protocol, statistical analysis plan)
- ▣ When the data will become available and for how long
- ▣ By what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism)

Funder Repositories & Publishing



BILL & MELINDA
GATES foundation



BILL & MELINDA GATES FOUNDATION OPEN ACCESS POLICY

Print

GENERAL INFORMATION

[How We Make Grants](#)

[How We Develop Strategy](#)

[Glossary of Terms](#)

[Information Sharing Approach](#)

[Open Access Policy](#) →

[Our Approach to Measurement and Evaluation](#)

[Evaluation Policy](#)

[Grantseeker FAQ](#)

[Grant Opportunities](#)

[Grant Seeking Resources](#)

[What We Do Not Fund](#)

[Reporting Scams](#)

[Tax Status Definitions](#)

RESOURCES FOR GRANTEES

[Our Commitment to Grantees](#)

[Grantee Profiles](#)

[Grantee & Partner Survey Report](#)

[Grantee Perception Report Summary 2013](#)

[Grantee Progress Report](#)

QUICK LINKS

[Awarded Grants](#)

[Contact Us](#)

[Program Related Investments](#)

The Bill & Melinda Gates Foundation is committed to information sharing and transparency. We believe that published research resulting from our funding should be promptly and broadly disseminated. We have adopted an Open Access policy that enables the unrestricted access and reuse of all peer-reviewed published research funded, in whole or in part, by the foundation, including any underlying data sets.

Related

[OPEN ACCESS POLICY FAQ](#)

As of January 1, 2015 our Open Access policy will be effective for all new agreements. During a two-year transition period, publishers will be permitted to apply up to a 12 month embargo period on the accessibility of the publication and its underlying data sets. This embargo period will no longer be allowed after January 1, 2017.

Our Open Access policy contains the following elements:

- 1. Publications Are Discoverable and Accessible Online.** Publications will be deposited in a specified repository(s) with proper tagging of metadata.
- 2. Publication Will Be On “Open Access” Terms.** All publications shall be published under the [Creative Commons Attribution 4.0 Generic License](#) (CC BY 4.0) or an equivalent license. This will permit all users of the publication to copy and redistribute the material in any medium or format and transform and build upon the material, including for any purpose (including commercial) without further permission or fees being required.
- 3. Foundation Will Pay Necessary Fees.** The foundation would pay reasonable fees required by a publisher to effect publication on these terms.
- 4. Publications Will Be Accessible and Open Immediately.** All publications shall be available immediately upon their publication, without any embargo period. An embargo period is the period during which the publisher will require a subscription or the payment of a fee to gain access to the publication. We are, however, providing a transition period of up to two years from the effective date of the policy (or until January 1, 2017). During the transition period, the foundation will allow publications in journals that provide up to a 12-month embargo period.
- 5. Data Underlying Published Research Results Will Be Accessible and Open Immediately.** The foundation will require that data underlying the published research results be immediately accessible and open. This too is subject to the transition period and a 12-month embargo may be applied.


Email questions to openaccess@gatesfoundation.org

Can we cure all diseases
in our children's lifetime?



Meta^α

WILEY



Chan Zuckerberg Meta

- ▣ Artificial Intelligence tool that:
- ▣ Analyzes millions of papers
- ▣ Helps scientists make connections in data
- ▣ Find collaborators
- ▣ Identifies and predicts impact (citations)
- ▣ BMJ, AMA, PNAS, Oxford University Press, PLOS all participating


Data Repositories





What is figshare


figshare is a cloud-based repository for data and publication management.




- figshare for publishers - portal and/or widget for supplementary material
- figshare for institutions - portal for data across the institution


What are Publishers using figshare for?

- Chemrxiv - ACS have developed a beta preprint server powered by



- Data Support Service - Springer Nature are piloting a service to offer support for supplementary data






Data Sharing Questions

- ▣ What has been your experience in trying to share data through one of these repositories?
- ▣ What worked?
- ▣ What were the problems?

	Dissemination	Registration	Validation	Curation	Promotion
	<i>Broadcasting the methods and findings of scientific inquiry</i>	<i>Capturing and assigning credit for a scientific discovery</i>	<i>Enabling peer review and other activities that validate the science</i>	<i>Capturing and categorizing relevant scientific information</i>	<i>Factoring scientific output into career advancement decisions</i>



ReadCube for Researchers

ReadCube is an innovative reference management platform used by millions of researchers worldwide.

- Global – users in every country
- 8 million users per month
- Highly engaged – over 20 minutes per article
- Web, desktop (Mac/PC) & mobile (ios/Android)
- Growing next-generation platform: Papers acquisition in 2016



Efforts to Create Standards for Reporting

- ▣ **STARD**

Standards for Reporting Diagnostic Accuracy
(Diagnostic Performance)

- ▣ **CONSORT**

Consolidated Standards of Reporting Trials
(Randomized Control Trials)

- ▣ **PRISMA**

Preferred Reporting Items for Systematic Reviews and
Meta-Analyses www.prisma-statement.org

Radiology Publication Information for Authors

Overview

Manuscript Types

Policies

Preparation

Submission

Editing

Checklist

Author Toolkit

Overview: Publishing in *Radiology*

Editorial and Publications Staff

Author Toolkit

We have put together this toolkit to aid in submission to our journal. Much of the information here will be helpful in design of studies, as well as in their submission.

[Before the Study Begins](#) ↓

[When Writing the Research Manuscript](#) ↓

[When Revising a Manuscript after Provisional Acceptance](#) ↓

[Proof Process](#) ↓

Before the Study Begins

Authorship. We follow [ICMJE guidelines on authorship](#). To be listed as an author, an individual should have made substantial contributions to all four categories established by the [ICMJE](#): (a) "conception and design, or acquisition of data, or analysis and interpretation of data," (b) "drafting the article or revising it critically for important intellectual content," (c) "final approval of the version to be published," and (d) "agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved." Please also see [our editorial on authorship](#). A full description of recommendations for the [Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals](#) is given by the International Committee of Medical Journal Editors. For the perspective of *Radiology* see [editorial by Drs. Kressel and Dixon](#).

When Writing the Research Manuscript

[Back to top ↑](#)

Please see our complete [Publication Information for Authors](#).

Refer to our list of [common errors](#) in manuscript preparation and avoid these issues.

For a description of how to document subject overlap in prior publications, see [a short description here](#).

It is important to appropriately attribute the source of any previously published material. Even if this material is from publications in your own group, it should be quoted and referenced. For a discussion on duplicate publications, please [see our editorial here](#).

To ensure that your final manuscript meets our Publication Information for Authors guidelines, please [fill out the checklist here](#).

For advice on how to format images for publication see the "Preparations" tab under "Figures" and [our editorial](#).

When Revising a Manuscript after Provisional Acceptance

[Back to top ↑](#)

If a manuscript is provisionally accepted, we will send you comments from the editor/deputy editor along with comments from the reviewers. In most cases, we will also send a manuscript with changes tracked.

Carefully review each of the suggested edits in the manuscript. Accept those with which you agree. You do not need to respond in detail to those changes that you accept that do not require further edits. Once you have accepted the changes use the document as the basis for your revision and for further edits.

If you reject a comment or if a comment requires explanation, then please annotate your responses to justify your action.

Reviewer comments are given for the most part as written by the reviewers. The editor/deputy editor will mark with an * those comments that require a response. Please be sure to indicate in your revised draft any deleted or changed text using the track changes option in Word.

In addition, in a separate document, detail the response to each of the comments with * in the acceptance letter.

Submit an annotated and clean copy of the manuscript, along with your detailed response letter.

Your revision will be reviewed by the editor/deputy editor as well as by the statistician. In most cases, you will be sent an update email requesting additional information or clarification. Be sure to respond as you did to the original decision letter, with an annotated version of your manuscript with changes tracked, a clean version of the manuscript, and a letter responding to the issues.

Proof Process

[Back to top ↑](#)

Once your manuscript has been edited for publication, you will be sent a link to the proofs. If you need to edit the pdf proofs, please see this list of [tips for editing pdfs](#).



Enhancing the QUALity and Transparency Of health Research

Visit the EQUATOR Spanish Website

Home Library Toolkits Courses & events News Blog About us Contact

Essential resources for writing and publishing health research



Library for health research reporting

The Library contains a comprehensive searchable database of reporting guidelines and also links to other resources relevant to research reporting.



Search for reporting guidelines



Not sure which reporting guideline to use?



Reporting guidelines under development




Visit the library for more resources



Reporting guidelines for main study types

Randomised trials	CONSORT	Extensions	Other
Observational studies	STROBE	Extensions	Other
Systematic reviews	PRISMA	Extensions	Other
Case reports	CARE		Other
Qualitative research	SRQR	COREQ	Other
Diagnostic / prognostic studies	STARD	TRIPOD	Other
Quality improvement studies	SQUIRE		Other
Economic evaluations	CHEERS		Other
Animal pre-clinical studies	ARRIVE		Other
Study protocols	SPIRIT	PRISMA-P	Other

[See all 259 reporting guidelines](#)



[Recommendations for writing trial protocols](#)

Toolkits

The EQUATOR Network works to improve the reliability and value of medical research literature by promoting transparent and accurate reporting of research studies.

Our Toolkits support different user groups, including:

EQUATOR highlights

3/03/2015 - Unique new EQUATOR course for health researchers



UK EQUATOR Centre Publication School, 6th-10th July 2015, St Anne's College, Oxford UK Fit for purpose: The secrets of success in writing, publishing, and disseminating research articles It is

News

Professor Doug Altman awarded BMJ Lifetime Achievement Award

7/05/2015
[BioMed Central to publish new journal: Research Integrity and Peer Review](#)
 2/04/2015

[DIET@NET partnership on a quest to improve the quality and comparability of dietary data in epidemiological and clinical studies](#)



Enhancing the QUALITY and
Transparency Of health Research



Visit the EQUATOR
Spanish Website

[Home](#) [Library](#) [Toolkits](#) [Courses & events](#) [News](#) [Blog](#) [About us](#) [Contact](#)

[Home](#) > [Library](#) > [Reporting guideline](#) > Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

Search for reporting guidelines

Use your browser's Back button to return to your search results



Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

Reporting guideline
provided for?
(i.e. exactly what the
authors state in the
paper)

Studies of diagnostic accuracy

[STARD checklist \(Word\)](#)

[STARD flow diagram \(PDF\)](#)

Full bibliographic
reference

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Clin Chem. 2003; 49(1):1-6. PMID: [12507953](#)

BMJ. 2003; 326(7379):41-44. PMID: [12511463](#)

Radiology. 2003; 226(1):24-28. PMID: [12511664](#)

Ann Intern Med. 2003; 138(1):40-44. PMID: [12513043](#)

Am J Clin Pathol. 2003; 119(1):18-22. PMID: [12520693](#)

Clin Biochem. 2003; 36(1):2-7. PMID: [12554053](#)

Clin Chem Lab Med. 2003; 41(1):68-73. PMID: [12636052](#)

Language

English

Relevant URLs
(full-text if available)

Full-text PDF documents of the STARD Statement, checklist, flow diagram and the Explanation and Elaboration document are available from: <http://www.stard->



Reporting guidelines for main study types

[Randomised trials](#)

[CONSORT](#)

[Extensions](#)

[Observational studies](#)

[STROBE](#)

[Extensions](#)

[Systematic reviews](#)

[PRISMA](#)

[Extensions](#)

[Case reports](#)

[CARE](#)

[Qualitative research](#)

[SRQR](#)

[COREQ](#)

[Diagnostic /
prognostic studies](#)

[STARD](#)

[TRIPOD](#)

[Quality improvement
studies](#)

[SQUIRE](#)

[Economic evaluations](#)

[CHEERS](#)

[Animal pre-clinical
studies](#)

[ARRIVE](#)

[Study protocols](#)

[SPIRIT](#)

[PRISMA-P](#)

Translations

Some reporting guidelines are also available in languages other than English. Find out more in our [Translations section](#).

About the Library

For information about Library scope and content, identification of reporting guidelines and inclusion/exclusion criteria please visit [About the Library](#).

Patrick M. Bossuyt
Johannes B. Reitsma
David E. Bruns
Constantine A. Gatsonis
Paul P. Glasziou
Les M. Irwig
Jeroen G. Lijmer
David Moher
Drummond Rennie
Henrica C. W. de Vet
For the STARD Group

Index terms:

Radiology and radiologists, research
Special Reports

Published online before print

10.1148/radiol.2261021292

Radiology 2003; 226:24–28

Abbreviation:

STARD = Standards for Reporting of
Diagnostic Accuracy

¹ From the Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, the Netherlands (P.M.B., J.B.R., J.G.L.); Department of Clinical Chemistry, University of Virginia Health System, Charlottesville (D.E.B.); Center for Statistical Sciences, Brown University, Providence, RI (C.A.G.); Department of Social and Preventive Medicine, Mayne Medical School, Herston, Australia (P.P.G.); Department of Public Health and Community Medicine, University of

Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative¹

OBJECTIVE: To improve the accuracy and completeness of reporting of studies of diagnostic accuracy, to allow readers to assess the potential for bias in the study and to evaluate its generalisability.

METHODS: The Standards for Reporting of Diagnostic Accuracy (STARD) steering group searched the literature to identify publications on the appropriate conduct and reporting of diagnostic studies and extracted potential items into an extensive list. Researchers, editors, and members of professional organisations shortened this list during a two-day consensus meeting with the goal of developing a checklist and a generic flow diagram for studies of diagnostic accuracy.

RESULTS: The search for published guidelines regarding diagnostic research yielded 33 previously published checklists, from which we extracted a list of 75 potential items. At the consensus meeting, participants shortened the list to a 25-item checklist, using evidence, whenever available. A prototypical flow diagram provides information about the method of patient recruitment, the order of test execution and the numbers of patients undergoing the test under evaluation, the reference standard or both.


CONCLUSIONS: Evaluation of research depends on complete and accurate reporting. If medical journals adopt the checklist and the flow diagram, the quality of reporting of studies of diagnostic accuracy should improve to the advantage of the clinicians, researchers, reviewers, journals, and the public.

How well are studies reported?

112 Diagnostic accuracy studies published in 2012

Item	Reported
Inclusion and exclusion criteria	65%
Participant sampling: consecutive vs. random vs. convenience	55%
Blinding of index test readers	58%
Baseline characteristics (age, sex, presenting symptoms)	61%

Adherence to STARD



STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies¹

Patrick M. Bossuyt, PhD

Johannes B. Reitsma, MD, PhD

David E. Bruns, MD

Constantine A. Gatsonis, PhD

Paul P. Glasziou, MRCGP, FRACGP, PhD, MBBS

Les Irwig, MBBS, PhD

Jeroen G. Lijmer, MD, PhD

David Moher, MD, PhD

Drummond Rennie, MD, MACP, FRCP

Henrica C.W. de Vet, PhD

Incomplete reporting has been identified as a major source of avoidable waste in biomedical research. Essential information is often not provided in study reports, impeding the identification, critical appraisal, and replication of studies. To improve the quality of reporting of diagnostic accuracy studies, the Standards for Reporting of Diagnostic Accuracy Studies (STARD) statement was developed. Here we present STARD 2015, an updated list of 30 essential items that should be included in every report of a diagnostic accuracy study. This update incorpo-

Table 1

The STARD 2015 List

Section and Topic	No.	Item
TITLE OR ABSTRACT		
	1	Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity, specificity, predictive values, or AUC)
ABSTRACT		
	2	Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD for Abstracts)
INTRODUCTION		
	3	Scientific and clinical background, including the intended use and clinical role of the index test
	4	Study objectives and hypotheses
METHODS		
Study design	5	Whether data collection was planned before the index test and reference standard were performed (prospective study) or after (retrospective study)
Participants	6	Eligibility criteria
	7	On what basis potentially eligible participants were identified (such as symptoms, results from previous tests, inclusion in registry)
	8	Where and when potentially eligible participants were identified (setting, location and dates)
	9	Whether participants formed a consecutive, random or convenience series
Test methods	10a	Index test, in sufficient detail to allow replication
	10b	Reference standard, in sufficient detail to allow replication
	11	Rationale for choosing the reference standard (if alternatives exist)
	12a	Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing pre-specified from exploratory
	12b	Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing pre-specified from exploratory
	13a	Whether clinical information and reference standard results were available to the performers/readers of the index test
	13b	Whether clinical information and index test results were available to the assessors of the reference standard
Analysis	14	Methods for estimating or comparing measures of diagnostic accuracy
	15	How indeterminate index test or reference standard results were handled
	16	How missing data on the index test and reference standard were handled
	17	Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory
	18	Intended sample size and how it was determined
RESULTS		
Participants	19	Flow of participants, using a diagram
	20	Baseline demographic and clinical characteristics of participants
	21a	Distribution of severity of disease in those with the target condition
	21b	Distribution of alternative diagnoses in those without the target condition
	22	Time interval and any clinical interventions between index test and reference standard
Test results	23	Cross tabulation of the index test results (or their distribution) by the results of the reference standard
	24	Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)
	25	Any adverse events from performing the index test or the reference standard
DISCUSSION		
	26	Study limitations, including sources of potential bias, statistical uncertainty, and generalisability
	27	Implications for practice, including the intended use and clinical role of the index test
OTHER INFORMATION		
	28	Registration number and name of registry
	29	Where the full study protocol can be accessed
	30	Sources of funding and other support; role of funders

Pay attention to the guidelines and Checklists

30 item STARD Checklist is an excellent guide for any clinical manuscript!

Prospective or Retrospective

Inclusion/Exclusion Criteria

Sequential subject enrollment, Age and gender distribution.

Data acquisition: Who?, Experience?, Blinded?, Consensus?

Reference Standard=Index Test well defined, documented in the literature?

Data Interpretation: Who? (Any Industry Affiliation)

Content Discovery: indexing technology.

100+ publishing partners participating in

ReadCube's content discovery & enhancement program



Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors

Table. Examples of Data Sharing Statements That Fulfill These ICMJE Requirements*

	Example 1	Example 2	Example 3	Example 4
Will individual participant data be available (including data dictionaries)?	Yes	Yes	Yes	No
What data in particular will be shared?	All of the individual participant data collected during the trial, after deidentification.	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).	Not available
What other documents will be available?	Study Protocol, Statistical Analysis Plan, Informed Consent Form, Clinical Study Report, Analytic Code	Study Protocol, Statistical Analysis Plan, Analytic Code	Study Protocol	Not available
When will data be available (start and end dates)?	Immediately following publication. No end date.	Beginning 3 months and ending 5 years following article publication.	Beginning 9 months and ending 36 months following article publication.	Not applicable
With whom?	Anyone who wishes to access the data.	Researchers who provide a methodologically sound proposal.	Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.	Not applicable
For what types of analyses?	Any purpose.	To achieve aims in the approved proposal.	For individual participant data meta-analysis.	Not applicable
By what mechanism will data be made available?	Data are available indefinitely at (Link to be included).	Proposals should be directed to xxx@yyy . To gain access, data requestors will need to sign a data access agreement. Data are available for 5 years at a third party website (Link to be included).	Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).	Not applicable

* These examples are meant to illustrate a range of, but not all, data sharing options.

To: Jeremy Nielsen

Subject: RSNA and the Chan Zuckerberg Initiative follow-up

Hi Jeremy,

As per my recent email, I am hoping to discuss [the Chan Zuckerberg Initiative's](#) interest in indexing RSNA content. We have a free literature discovery engine, [Meta](#), that enables researchers around the world to stay on top of developments in their fields, explore landmark papers, and learn about important scientific advances in real time. Meta has built a knowledge graph that includes 30 million+ scholarly articles, and we would like to add your content to the mix.

As per my earlier message, publishers (including BMJ, the American Medical Association, PNAS, Taylor & Francis, Oxford University Press, Annual Reviews, PLOS, and dozens more) are working with the Chan Zuckerberg Initiative and Meta for several reasons. The first is that the Meta discovery engine delivers readers back to their sites. We do not serve the full text or pass our users off to file-sharing services. All traffic flows to you. Additionally, Meta will be providing a number of free, AI-driven tools to our publisher partners. These tools provide insights and predictions pertaining to manuscripts, articles, journals and individual entities in science. Finally, the Chan Zuckerberg Initiative and Meta are noncommercial entities with the sole aim of improving efficiencies in research discovery.

Please let me know if we can discuss making RSNA content discoverable in the Meta service. Thank you in advance for your reply.

Best Regards,
Greg

Greg Tananbaum
Strategic Partnerships, Meta



Content Delivery: Enhanced PDF technology

- ▣ Started as collaboration with NPG
- ▣ Indexing of publisher's metadata
 - to create interactive PDFs
 - to enhance discoverability via Readcube's discovery tools



Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors

ICMJE will require the following as conditions of consideration for publication of a clinical trial report in our member journals:

1. As of 1 July 2018 manuscripts submitted to ICMJE journals that report the results of clinical trials must contain a data sharing statement
2. Clinical trials that begin enrolling participants on or after 1 January 2019 must include a data sharing plan in the trial's registration.

The ICMJE's policy regarding trial registration is explained at www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html.

If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record.